Publikationen in Zusammenarbeit mit Forschern von Universitat Autònoma de Barcelona (25)

2024

  1. Rate of recurrence after discontinuing anticoagulation in patients with venous thromboembolism within 30 days after COVID-19 vaccine

    European Journal of Clinical Investigation

2023

  1. Gene therapy restores the transcriptional program of hematopoietic stem cells in Fanconi anemia

    Haematologica, Vol. 108, Núm. 10, pp. 2652-2663

2022

  1. Cancer Histology and Natural History of Patients with Lung Cancer and Venous Thromboembolism

    Cancers, Vol. 14, Núm. 17

  2. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus

    ESMO Open, Vol. 7, Núm. 2

  3. Predictors of use of direct oral anticoagulants in patients with venous thromboembolism: Findings from the Registro Informatizado Enfermedad Tromboembólica registry

    Frontiers in Medicine, Vol. 9

2021

  1. A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia

    Cancer, Vol. 127, Núm. 12, pp. 2003-2014

  2. Clinical characteristics and 3-month outcomes in cancer patients with incidental versus clinically suspected and confirmed pulmonary embolism

    European Respiratory Journal, Vol. 58, Núm. 1

  3. PICO questions and DELPHI methodology for the management of venous thromboembolism associated with COVID-19

    Viruses, Vol. 13, Núm. 11

  4. The mutational landscape of acute myeloid leukaemia predicts responses and outcomes in elderly patients from the pethema-flugaza phase 3 clinical trial

    Cancers, Vol. 13, Núm. 10

2020

  1. Real-Time Dissemination of Aggregate Data on Presentation and Outcomes of Patients With Venous Thromboembolism: The RIETE Infographics Project

    Clinical and Applied Thrombosis/Hemostasis, Vol. 26

2019

  1. Natural history of patients with venous thromboembolism and hereditary hemorrhagic telangiectasia. Findings from the RIETE registry

    Orphanet Journal of Rare Diseases, Vol. 14, Núm. 1

2018

  1. Cancer-associated thrombosis: Beyond clinical practice guidelines-A multidisciplinary (SEMI-SEOM-SETH) expert consensus

    TH Open, Vol. 2, Núm. 4, pp. e373-e386

2015

  1. Critical analysis of the stringent complete response in multiple myeloma: Contribution of sFLC and bone marrow clonality

    Blood, Vol. 126, Núm. 7, pp. 858-862

  2. Fondaparinux in the initial and long-term treatment of venous thromboembolism

    Thrombosis Research, Vol. 135, Núm. 2, pp. 311-317

2013

  1. Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Matched Comparison to a Melphalan-Only Approach

    Biology of Blood and Marrow Transplantation, Vol. 19, Núm. 1, pp. 69-74

  2. Pulmonary embolism and 3-month outcomes in 4036 patients with venous thromboembolism and chronic obstructive pulmonary disease: Data from the RIETE registry

    Respiratory Research, Vol. 14, Núm. 1

  3. The Effect of a Physical Activity Program on the Total Number of Primary Care Visits in Inactive Patients: A 15-Month Randomized Controlled Trial

    PLoS ONE, Vol. 8, Núm. 6

2012

  1. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia

    Leukemia, Vol. 26, Núm. 7, pp. 1517-1526

2007

  1. Clinical outcome of patients with venous thromboembolism and renal insufficiency. Findings from the RIETE registry

    Thrombosis and Haemostasis, Vol. 98, Núm. 4, pp. 771-776

2006

  1. Ectopic nucleolus organizer regions in a patient with premature ovarian failure

    Fertility and Sterility, Vol. 86, Núm. 4, pp. 1001.e15-1001.e16